Search

everythinglearnresearchcommunity

for

Search:↓

Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.

Stem cell vesicles reduced eczema symptoms in mice safely.

New treatments for alopecia show promise in restoring hair growth by targeting immune and hormonal factors.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.

Chronic autoimmune urticaria can be managed with specific therapies and requires improved diagnosis and treatment methods.

Special cells can help regrow hair in alopecia areata.

Alopecia areata is caused by immune attacks on hair follicles, affecting hair growth and quality of life.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.

Ruxolitinib helped regrow hair in a woman with a blood disorder and complete hair loss.

Alopecia areata in Saudi Arabia is costly, mainly due to lost productivity and drug costs.

The immune processes causing VKH and vitiligo are similar in dogs and humans.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.

Upadacitinib may cause hair loss.

RV3466F lotion significantly reduces hair loss and improves acute telogen effluvium.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.

Tofacitinib is effective and safe for treating severe alopecia areata.

JAK inhibitors show promise for treating skin diseases effectively and safely.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

JAK inhibitors help treat alopecia areata but have high recurrence after stopping.